Epidemiological and outcome data in Japanese patients with deep vein thrombosis with and without malignancy
There are very few epidemiological studies on Japanese patients with deep vein thrombosis (DVT). In particular, mortality rate differences in Japanese DVT patients with and without malignancy have rarely been evaluated. To elucidate these differences, we enrolled 211 patients who had been diagnosed with de-novo acute DVT of the pelvis or lower extremities between January 2012 and December 2015. The clinical characteristics, treatment information, and follow-up data were retrospectively assessed. We compared these variables in patients with (n = 120) and without (n = 91) concomitant malignancies. The median age of patients was 67 years, 33.7% were male, and 82.9% patients were treated with oral anticoagulants including direct oral anticoagulants. The clinical characteristics and treatment provided were almost identical in the two groups with some exceptions. Three-year survival rates of the total population, patients with malignancy, and patients without malignancy were 80.6, 67.6, and 97.6%, respectively (log-rank p < 0.001). Multivariable Cox regression analysis demonstrated that malignancy was independently associated with high risk of 3-year all-cause mortality with an adjusted hazard ratio of 9.1 (95% confidence interval; 2.1–39.0, p = 0.003). Bootstrap validation demonstrated an acceptable index corrected slope of 0.766 without significant overfitting in a multivariable model. In conclusion, we analyzed epidemiological data on Japanese patients with DVT. Malignancy was independently associated with increased 3-year all-cause mortality.
KeywordsDeep venous thrombosis Epidemiological data Malignancy Mortality
We would like to express our heartfelt gratitude to the Japan Society of Clinical Research (http://www.japanscr.org/) for their dedicated support.
Compliance with ethical standards
All procedures performed in the study involving human participants were in accordance with the ethical standards of each institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Garcia DA, Baglin TP, Weitz JI, Samama MM, American College of Chest Physicians (2012) Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e24S–e43SCrossRefPubMedPubMedCentralGoogle Scholar
- 2.Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, Gibbs JS, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Vonk Noordegraaf A, Zamorano JL, Zompatori M, Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) (2014) 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 35:3033–3069CrossRefPubMedGoogle Scholar
- 14.Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE (1991) A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 151:933–938CrossRefPubMedGoogle Scholar
- 24.Carrier M, Lazo-Langner A, Shivakumar S, Tagalakis V, Zarychanski R, Solymoss S, Routhier N, Douketis J, Danovitch K, Lee AY, Le Gal G, Wells PS, Corsi DJ, Ramsay T, Coyle D, Chagnon I, Kassam Z, Tao H, Rodger MA, Investigators SOME (2015) Screening for occult cancer in unprovoked venous thromboembolism. N Engl J Med 373:697–704CrossRefPubMedGoogle Scholar
- 25.Prandoni P, Bernardi E, Valle FD, Visonà A, Tropeano PF, Bova C, Bucherini E, Islam MS, Piccioli A (2016) Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: A. multicenter, controlled, randomized clinical trial. Semin Thromb Hemost 42:884–890CrossRefPubMedGoogle Scholar
- 26.Van Doormaal FF, Terpstra W, Van Der Griend R, Prins MH, Nijziel MR, Van De Ree MA, Büller HR, Dutilh JC, ten Cate-Hoek A, Van Den Heiligenberg SM, Van Der Meer J, Otten JM (2011) Is extensive screening for cancer in idiopathic venous thromboembolism warranted? J Thromb Haemost 9:79–84CrossRefPubMedGoogle Scholar
- 27.Galanaud J-P, Sevestre-Pietri MA, Bosson JL, Laroche JP, Righini M, Brisot D, Boge G, van Kien AK, Gattolliat O, Bettarel-Binon C, Gris JC, Genty C, Quere I; OPTIMEeV-SFMV Investigators (2009) Comparative study on risk factors and early outcome of symptomatic distal versus proximal deep vein thrombosis: results from the OPTIMEV study. Thromb Haemost 102:493–500PubMedGoogle Scholar
- 30.Tagaya M, Yoshikawa D, Sugishita Y, Yamauchi F, Ito T, Kamada T, Yoshinaga M, Mukaide D, Fujiwara W, Yokoi H, Hayashi M, Watanabe E, Ishii J, Ozaki Y, Izawa H (2016) Prescription patterns of oral anticoagulants for patients with non-valvular atrial fibrillation: experience at a Japanese single institution. Heart Vessels 31:957–962CrossRefPubMedGoogle Scholar